Ezra E.W. Cohen

University of San Diego — United States

Medicine · Health Sciences

85h-index37.4kcitations867works2.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Head and Neck Cancer Studies(297), Lung Cancer Treatments and Mutations(219), Cancer Immunotherapy and Biomarkers(159), PI3K/AKT/mTOR signaling in cancer(82), Lung Cancer Research Studies(67)

Publications861 total

Genome-wide CRISPR Screening Reveals a PKA-Driven Resistance Mechanism to Metformin for Oral Cancer Prevention That Can Be Exploited by Combination with NSAIDs
Cancer Prevention Research·2025Open Access
Table S2 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
2025Open Access
Table S3 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
2025Open Access
Censoring rules 3 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
2025Open Access
Supplementary Table S3 from A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck
2025Open Access
Supplementary Table S1 from A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck
2025Open Access
Supplementary Table S2 from A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck
2025Open Access
Table S1 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
2025Open Access
Methodology and Criteria for MDSCs 2 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
2025Open Access
Inclusion and Exclusion Criteria 1 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
2025Open Access
Table S4 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
2025Open Access
133 MAIT cell abundance within solid tumors is associated with key clinical characteristics
Regular and Young Investigator Award Abstracts·2025Open Access
157 A novel multi-omic algorithm to predict real-world outcomes among patients with rare, advanced, solid cancers treated with off-label immune checkpoint inhibitors
Regular and Young Investigator Award Abstracts·2025Open Access
124 A platform to identify tumor-specific neoantigens and corresponding T cell receptors
Regular and Young Investigator Award Abstracts·2025Open Access
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer
UNC Libraries·2025Open Access
A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck.
UNC Libraries·2025Open Access
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study
Journal of Clinical Oncology·2025· 7 citedOpen Access
The spontaneous neoantigen-specific CD4 <sup>+</sup> T-cell response to a growing tumor is functionally and phenotypically diverse
Journal for ImmunoTherapy of Cancer·2025· 2 citedOpen Access
Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
Journal for ImmunoTherapy of Cancer·2025· 3 citedOpen Access
Pathologic response to neoadjuvant sequenced, lymphatic-sparing SBRT plus pembrolizumab in HPV-negative head and neck squamous cell carcinoma.
Journal of Clinical Oncology·2025· 1 cited
page 1 of 44Next →

Frequent Co-authors

Everett E. Vokes(15), Tanguy Y. Seiwert(9), Lisa Licitra(8), Loren K. Mell(7), Mark W. Lingen(6), Ranee Mehra(5), Kevin J. Harrington(5), Ralph R. Weichselbaum(5), Joseph A. Califano(5), Barbara Burtness(4), Steven I. Sherman(4), Karen Messer(4), Quynh‐Thu Le(4), Kerstin Stenson(4), Roger B. Cohen(4), Daniel J. Haraf(4), Alfredo Molinolo(4), J. Silvio Gutkind(4), Andrew B. Sharabi(4), Marcia S. Brose(3)